Pharmaceutical and healthcare market in Poland 2009

Request sample pages/interactive screenshare

1. Report methodology

2. Executive summary

3. Overview of the pharmaceutical market in Poland

• Key events and trends in 2008-2009
• Key events and trends anticipated for 2009-2010
• Size of Polish pharmaceutical market
• Pharmaceutical market in 2002-2011
• Pharmacy sales in 2002-2008
• Development forecasts for pharmacy sales in 2009-2011
• Number of packages sold in 2002-2008
• Domestic and foreign pharmaceuticals
• Original and generic pharmaceuticals
• Overview of the hospital drug market in Poland
• Value of hospital market in 2000-2010
• Financial standing of public healthcare facilities
• Drug therapy programmes
• Spending on chemotherapy
• Drug prices
• Average drug prices on the pharmacy market
• Average drug prices on the hospital market
• Average prices of domestic and foreign pharmaceuticals
• Prices on aggregate pharmacy market
• Prices of Rx drugs
• Prices of refunded drugs
• Average prices of innovative and generic drugs
• Average prices in therapeutic groups
• Analysis of ATC groups, showcasing Rx drugs
• Analysis of ATC subgroups, showcasing Rx drugs
• Average prices of concern drugs
• Prices on the pharmacy market
• Rx drug prices
• Drug prices in Poland and in other European countries
• Drug reimbursement in Poland
• NFZ expenditure on drug reimbursement
• Share of reimbursement in pharmacy trade
• Structure of drug reimbursement
• Reimbursement structure by reimbursement type
• Reimbursement structure by therapeutic groups
• Reimbursement structure by domestic and foreign drugs
• Reimbursement structure by active substances
• Reimbursement structure by product
• Reimbursement structure by manufacturer
• Legislative changes and their impact on the drug reimbursement market
• New reimbursement lists
• Amendment to Pharmaceutical Law
• Foreign trade
• Export
• Import

4. Pharmacy market by therapeutic groups

• Market value shares of ATC groups
• Pharmacy market
• Rx market
• Market volume shares of ATC groups
• Pharmacy market
• Rx market
• Alimentary tract and metabolism
• Market size and forecasts
• Key categories of drugs used in alimentary tract and metabolic diseases
• Drugs used in diabetes
• Vitamins and mineral supplements
• Antacids, antiflatulents and anti-ulcerants
• Antidiarrhoeals, oral electrolyte replacers and intenstinal anti-inflammatories
• Antiobesity preparations
• Best selling preparations
• Cardiovascular system
• Market size and forecasts
• Key categories of drugs used in cardiovascular diseases
• Agents acting on the renin-angiotensin system
• Lipid regulators
• Beta blocking agents
• Antihypertensives
• Best selling preparations
• Central nervous system
• Market size and forecasts
• Key categories of drugs used in central nervous system diseases
• Analgesics
• Psycholeptics
• Psychoanaleptics
• Best selling preparations
• Respiratory system
• Market size and forecasts
• Key categories of drugs used in respiratory system diseases
• Anti-asthma and COPD products
• Cough and cold preparations
• Systemic antihistamines
• Nasal preparations
• Best selling preparations
• Anti-infectives
• Market size and forecasts
• Key categories of anti-infectives
• Systemic antibacterials
• Vaccines
• Best selling preparations
• Musculo-skeletal system
• Market size and forecasts
• Key categories of drugs used in musculo-skeletal diseases
• Anti-inflammatory and anti-rheumatic products
• Topical anti-rheumatics
• Drugs for disorders of the musculo-skeletal system
• Best selling preparations
• Genito-urinary system
• Market size and forecasts
• Key categories of drugs affecting genito-urinary system
• Sex hormones and products with similar desired effects, systemic use only
• Urologicals
• Best selling preparations
• Dermatologicals
• Market size and forecasts
• Key categories of dermatologicals
• Topical corticosteroids
• Dermatological antifungals
• Best selling preparations
• Blood and blood forming organs
• Market size and forecasts
• Key categories of drugs used in diseases of the blood and blood forming organs
• Antithrombotic agents
• Anti-anaemic preparations
• Best selling preparations
• Antineoplastic and immunomodulating agents
• Market size and forecasts
• Key categories of antineoplastic and immunomodulating agents
• Cytostatic hormone therapy
• Immunostimulating agents
• Immunosuppressants
• Best selling preparations
• Other ATC groups
• Sensory organs
• Systemic hormonal preparations
• Parasitology
• Various

5. Pharmaceutical companies in Poland

• Number and classification of pharmaceutical manufacturers in Poland
• Manufacturers of pharmaceutical substances
• Drug manufacturers
• Economic analysis of Polish pharmaceutical sector
• Output of selected pharmaceutical products
• Revenues
• Profit
• Operating expenses
• Employment
• Staffing levels
• Labour productivity
• Average remuneration
• Investments in the Polish pharmaceutical sector in 2006
• Investment number
• Investment value
• Largest foreign investments in Polish pharmaceutical industry 2007-2008
• Expenditure on intangible fixed assets
• Top drug makers in Poland
• Top players on pharmacy market
• Top players on the Rx market
• Profiles of key players

6. Demographic trends

• Population
• Natural population growth
• Ageing of society
• Life expectancy
• Gender structure
• Degree of urbanisation

7. Epidemiological trends

• The main health problems of Poles
• Main causes of death
• Key statistics
• Poland compared with other European countries
• Epidemiology of selected diseases in Polish society
• Cardiovascular system diseases
• Neoplasms
• Diseases of the central nervous system
• Respiratory system diseases
• Diseases of the alimentary tract and metabolism

8. Consumer behaviour

• Health assessment
• What do Poles do to be healthy?
• Sources of information about health and illnesses
• Poles’ opinion about generic drugs
• Poles’ opinions about innovative drugs
• Factors influencing the purchase of OTC drugs
• Frequency of OTC drug purchases
• Most popular OTC drugs
• Place of purchase of OTC drugs
• Drug use in illness

9. Macroeconomic trends

• GDP growth
• Inflation
• Unemployment
• Wages

10. Regulatory environment

• Regulations and institutions governing the pharmaceutical market in Poland
• Key changes introduced by the “large amendment” to the Pharmaceutical Law
• Key changes introduced by the amended Healthcare Act
• Anti-corruption provisions
• Changes in reimbursement process
• Greater control over the NFZ
• Ordinance on Drug Advertising
• Visits of medical representatives at public healthcare centres
• Simultaneous advertising of several products
• Risk warnings
• Ban on audiovisual advertising in pharmacies
• Compliance with Medicinal Product Characteristics
• Transition provisions
• Key amendments introduced by the “minor amendment” to the Pharmaceutical Law
• Fixed prices and margins for reimbursed drugs
• Anti-concentration regulations
• Ban on advertising pharmacies
• Changes in monitoring adverse reactions
• Other regulations
• Harmonisation of registration documentation
• URPL Act

11. Distribution

• Key events and trends on the distribution market in 2007-2009
• Trends expected on the distribution market in 2009-2011
• Key players on the drug distribution market
• Pharmaceutical wholesalers
• Wholesalers in Poland: number and business profiles
• The largest players on the Polish wholesale market
• Pharmacy distribution
• Pharmacy count
• Financial standing of Polish pharmacies
• Pharmacy chains
• Internet pharmacies

12. Healthcare market in Poland

• Healthcare system in Poland
• Sources of financing of the public healthcare system
• Healthcare financing
• Healthcare costs
• Market of private medical services in Poland
• Other data on health care in Poland

13. List of graphs

14. List of tables

15. About PMR

16. About PharmaExpert

List of graphs

1. Value (PLN bn) and y-o-y change of sales on the pharmaceutical market in Poland, 2002-2011
2. Percentage shares of OTC and Rx drugs in the pharmacy market in Poland, 2008
3. Value (PLN bn) and y-o-y change of sales on the pharmaceutical market in Poland, 2002-2011
4. Value (PLN bn) and y-o-y change of sales of Rx drugs on the pharmaceutical market in Poland, 2002-2011
5. Share of domestic and foreign drugs in value of pharmacy sales in Poland, 2002-2008
6. Share of domestic and foreign drugs in value of Rx pharmacy sales in Poland, 2002-2008
7. Share of domestic and foreign drugs in number of packages sold in Poland, 2002-2008
8. Share of domestic and foreign Rx drugs in number of packages sold in Poland, 2002-2008
9. Value (PLN bn) and y-o-y change of sales of domestic drugs in Poland, 2002-2011
10. Value (PLN bn) and y-o-y change of sales of foreign drugs in Poland, 2002-2011
11. Sales value of generic and original drugs in Poland (PLN m), 2004-2007
12. Sales volume of packages of generic and original drugs in Poland (million of units), 2004-2007
13. Value share of generics in Polish pharmaceutical market, Q3 2007-Q3 2008
14. Shares of generic and original drugs in Rx market value in Poland (%), 2004-2007
15. Shares of original and generic drugs in the value of Polish pharmaceutical market relative to select countries (%), June 2007-June 2008
16. Quantitative share of generics in Polish pharmaceutical market, Q3 2007-Q3 2008
17. Volume share of generic and original drugs in Rx market in Poland (%), 2004-2007
18. Volume share of generic drugs in Polish Rx market relative to select countries (%), June 2007-June 2008
19. Value (PLN bn) and y-o-y change of hospital pharmaceutical market in Poland, 2000-2011
20. Debt due from independent public healthcare centres in Poland (PLN bn), Q1 2005-Q4 2008
21. Total debt of independent healthcare centres in Poland (PLN m), Q4 2004-Q4 2008
22. NFZ spending on drug therapy programmes and y-o-y change in Poland (PLN m), 2005-2009
23. NFZ spending on chemotherapy and y-o-y change in Poland (PLN m), 2006-2009
24. Share of unused funds allocated to chemotherapy reimbursement in Poland, H1 2008
25. Average drug prices on pharmacy market in Poland (PLN), 2002-2008
26. Change in prices of reimbursed drugs in Polish pharmacies, January-December 2008
27. Average drug prices in in-patient treatment in Poland (PLN), 2004-2007
28. Average prices of domestic and foreign drugs sold on the Polish pharmacy market (PLN), 2002-2008
29. Average prices of domestic and foreign Rx drugs sold on the Polish pharmacy market (PLN), 2002-2008
30. Average prices of domestic and foreign refunded drugs sold on the Polish pharmacy market (PLN), 2002-2008
31. Average prices of innovative and generic Rx drugs on pharmacy market in Poland (PLN), 2004-2007
32. Average drug prices by ATC groups in Poland (PLN), 2003, 2007 and 2008
33. Average Rx drug prices by ATC groups in Poland (PLN), 2003, 2007 and 2008
34. Highest growth rates in ATC subgroups on Polish pharmacy market, 2008
35. Highest growth rates in ATC subgroups on Polish pharmacy Rx market, 2008
36. Greatest decreases in ATC subgroups on Polish pharmacy market, 2008
37. Greatest decreases in ATC subgroups on Polish Rx pharmacy market, 2008
38. Average drug prices of largest pharma concerns in Poland (PLN), 2006-2008
39. Average Rx drug prices of largest pharma concerns in Poland (PLN), 2006-2008
40. Average manufacturer price (MSRP) per comparable drug unit in Poland and other European countries, 2008
41. Value of the NFZ’s expenditure for refunded drugs compared to value of expenditure for healthcare in Poland (PLN m), 2003-2009 62] Percentage share of reimbursement in pharmacy trade in Poland, H1 2006- H2 2008
42. Drug reimbursement in Poland by reimbursement type, in value terms, 2004-2007
43. Drug reimbursement in Poland by reimbursement type, in volume terms, 2004-2007
44. Structure of drug reimbursement in Poland, by ATC groups, 2007
45. Structure of sales of reimbursed drugs in Poland for domestic and foreign preparations, by value, 2002-2008
46. Structure of sales of reimbursed drugs in Poland for domestic and foreign preparations, by volume, 2002-2008
47. Drug refund levels in Poland and select European countries, 2007
48. Value ($ m) and y-o-y change of drug exports from Poland, 1996-H1 2008
49. Countries of destination for Polish drug exports by value of exports (PLN m) and y-o-y change, 2007
50. Countries of destination for Polish drug exports by value of exports (PLN m) and y-o-y change, H1 2008
51. Top increases in value of drug exports from Poland, by country, H1 2008
52. Value ($ bn) and y-o-y change of drug imports to Poland, 1996-H1 2008
53. Countries of origin of drug imports to Poland (PLN m) and y-o-y change in import value, 2007
54. Countries of origin of drug imports to Poland (PLN m) and y-o-y change in import value, H1 2008
55. Top increases in drug imports to Poland, by country, H1 2008
56. Pharmacy market by ATC categories in value terms in Poland, 2008
57. Pharmacy Rx market by ATC categories in value terms in Poland, 2008
58. Pharmacy market by ATC categories in volume terms in Poland, 2008
59. Pharmacy Rx market by ATC categories in volume terms in Poland, 2008
60. Sales value (PLN m) and y-o-y change of drugs used in alimentary tract and metabolic diseases in Poland, 2002-2011
61. Sales value (PLN m) and y-o-y change of Rx drugs used in alimentary tract and metabolic diseases in Poland, 2002-2011
62. Sales value (PLN m) and y-o-y change of largest categories of drugs used in alimentary tract and metabolic diseases in Poland, 2008
63. Sales value (PLN m) and y-o-y change of largest categories of Rx drugs used in alimentary tract and metabolic diseases in Poland, 2008
64. Sales value (PLN m) and y-o-y change of drugs used in cardiovascular diseases in Poland, 2002-2011
65. Sales value (PLN m) and y-o-y change of Rx drugs used in cardiovascular diseases in Poland, 2002-2011
66. Sales value (PLN m) and y-o-y change of largest categories of drugs used in cardiovascular diseases in Poland, 2008
67. Sales value (PLN m) and y-o-y change of largest categories of Rx drugs used in cardiovascular diseases in Poland, 2008
68. Sales value (PLN m) and y-o-y change of drugs used in central nervous system diseases in Poland, 2002-2011
69. Sales value (PLN m) and y-o-y change of Rx drugs used in central nervous system diseases in Poland, 2002-2011
70. Sales value (PLN m) and y-o-y change of largest categories of drugs used in central nervous system diseases in Poland, 2008
71. Sales value (PLN m) and y-o-y change of largest categories of Rx drugs used in central nervous system diseases in Poland, 2008
72. Sales value (PLN m) and y-o-y change of drugs used in respiratory system diseases in Poland, 2002-2011
73. Sales value (PLN m) and y-o-y change of Rx drugs used in respiratory system diseases in Poland, 2002-2011
74. Sales value (PLN m) and y-o-y change of categories of drugs used in respiratory system diseases in Poland, 2008
75. Sales value (PLN m) and y-o-y change of categories of Rx drugs used in respiratory system diseases in Poland, 2008
76. Incidence of asthma and wheezing/whistling in the chest in urban and rural Poland, 2006-2008
77. Incidence of allergic rhinitis and rhinitis in rural and urban Poland, 2006-2008
78. Sales value (PLN m) and y-o-y change of anti-infectives in Poland, 2002-2011
79. Sales value (PLN m) and y-o-y change of Rx anti-infectives in Poland, 2002-2011
80. Sales value (PLN m) and y-o-y change of largest categories of anti-infectives in Poland, pharmacy market and Rx market, 2008
81. Sales value (PLN m) and y-o-y change of drugs used in musculo-skeletal diseases in Poland, 2002-2011
82. Sales value (PLN m) and y-o-y change of Rx drugs used in musculo-skeletal diseases in Poland, 2002-2011
83. Sales value (PLN m) and y-o-y change of categories of drugs used in musculo-skeletal diseases in Poland, 2008
84. Sales value (PLN m) and y-o-y change of categories of Rx drugs used in musculo-skeletal diseases in Poland, 2008
85. Sales value (PLN m) and y-o-y change of drugs affecting genito-urinary system in Poland, 2002-2011
86. Value (PLN m) and y-o-y change of sales of Rx drugs affecting genito-urinary system in Poland, 2002-2011
87. Sales value (PLN m) and y-o-y change of categories of drugs affecting genito-urinary system in Poland, 2008
88. Sales value (PLN m) and y-o-y change of categories of Rx drugs affecting genito-urinary system in Poland, 2008
89. Sales value (PLN m) and y-o-y change of dermatologicals in Poland, 2002-2011
90. Sales value (PLN m) and y-o-y change of Rx dermatologicals in Poland, 2002-2011
91. Sales value (PLN m) and y-o-y change of largest categories of dermatologicals in Poland, 2008
92. Sales value (PLN m) and y-o-y change of largest categories of Rx dermatologicals in Poland, 2008
93. Sales value (PLN m) and y-o-y change of drugs used in diseases of the blood and blood forming organs in Poland, 2002-2011
94. Sales value (PLN m) and y-o-y change of Rx drugs used in diseases of the blood and blood forming organs in Poland, 2002-2011
95. Sales value (PLN m) and y-o-y change of largest categories of drugs used in diseases of the blood and blood forming organs in Poland, 2008
96. Sales value (PLN m) and y-o-y change of largest categories of Rx drugs used in diseases of the blood and blood forming organs in Poland, 2008
97. Sales value (PLN m) and y-o-y change of antineoplastic and immunomodulating agents in Poland, 2002-2011
98. Sales value (PLN m) and y-o-y change of Rx antineoplastic and immunomodulating agents in Poland, 2002-2011
99. Sales value (PLN m) and y-o-y change of categories of antineoplastic and immunomodulating agents in Poland, 2008
100. Sales value (PLN m) and y-o-y change of categories of Rx antineoplastic and immunomodulating agents in Poland, 2008
101. Sales value (PLN m) and y-o-y change of drugs used in disorders of the sensory organs in Poland, 2002-2011
102. Sales value (PLN m) and y-o-y change of Rx drugs used in disorders of the sensory organs in Poland, 2002-2011
103. Sales value (PLN m) and y-o-y change of categories of drugs used in disorders of the sensory organs in Poland, 2008
104. Sales value (PLN m) and y-o-y change of categories of Rx drugs used in disorders of the sensory organs in Poland, 2008
105. Sales value (PLN m) and y-o-y change of systemic hormonal preparations in Poland, 2002-2011
106. Sales value (PLN m) and y-o-y change of Rx systemic hormonal preparations in Poland, 2002-2011
107. Sales value (PLN m) and y-o-y change of categories of systemic hormonal preparations in Poland, 2008
108. Sales value (PLN m) and y-o-y change of categories of Rx systemic hormonal preparations in Poland, 2008
109. Sales value (PLN m) and y-o-y change of parasitology drugs in Poland, 2002-2011
110. Sales value (PLN m) and y-o-y change of Rx parasitology drugs in Poland, 2002-2011
111. Sales value (PLN m) and y-o-y change of categories of parasitology drugs in Poland, 2008
112. Sales value (PLN m) and y-o-y change of categories of Rx parasitology drugs in Poland, 2008
113. Sales structure of ATC group “various” in Poland, pharmacy market, 2008
114. Sales structure of ATC group “various” in Poland, Rx market, 2008
115. Size of manufacturers of basic pharmaceutical products (NACE 21.1) in Poland, 2007
116. Size of drugs and pharmaceutical preparations’ manufacturers (NACE 21.2) in Poland, 2007
117. Output of selected pharmaceutical products in Poland (tonnes), 2000-2007
118. Net revenues (PLN bn) and y-o-y change of Polish pharmaceutical sector, 2002-2007
119. Sales profit and y-o-y change of the pharmaceutical sector in Poland (PLN m), 2005-2007
120. Wages in pharmaceutical sector in Poland (PLN), 2006-2007
121. Structure of investments in Polish pharma industry, by NACE code, 2007
122. Cost estimate value (PLN m) and y-o-y change of new investments in Polish pharma industry, 2004-2007
123. Value of new investments in Polish pharma, by NACE type, 2007
124. Outlays on tangible assets in Polish pharma industry (PLN m), 2004-2007
125. Top 10 pharma concerns on the Polish pharmacy market in terms of sales value, 2008
126. Market shares of top 10 pharma concerns by sales value in sales volume (number of packages sold) on pharmacy market in Poland, 2008
127. Top 10 pharma manufacturers on the Polish pharmacy market in terms of sales value, 2008
128. Market shares of top 10 pharma manufacturers by sales value in sales volume (number of packages sold) on pharmacy market in Poland, 2008
129. Top 10 pharma concerns on the Polish Rx pharmacy market in terms of sales value, 2008
130. Market shares of top 10 pharma concerns by sales value in sales volume (number of packages sold) on Rx pharmacy market in Poland, 2008
131. Top 10 pharma manufacturers on the Polish Rx pharmacy market in terms of sales value, 2008
132. Market shares of top 10 pharma manufacturers by sales value in sales volume (number of packages sold) on Rx pharmacy market in Poland, 2008
133. Novartis’ sales (PLN m) and y-o-y change on Polish pharmacy market, 2002-2008
134. Novartis’ Rx sales (PLN m) and y-o-y change on Polish pharmacy market, 2002-2008
135. GSK sales (PLN m) and y-o-y growth on Polish pharmacy market, 2002-2008
136. GSK Rx sales (PLN m) and y-o-y change on Polish pharmacy market, 2002-2008
137. Polpharma sales (PLN m) and y-o-y change on the Polish pharmacy market, 2002-2008
138. Polpharma Rx sales (PLN m) and y-o-y change on Polish pharmacy market, 2002-2008
139. Sanofi-Aventis sales (PLN m) and y-o-y change on the Polish pharmacy market, 2002-2008
140. Sanofi-Aventis Rx sales (PLN m) and y-o-y change on the Polish pharmacy market, 2002-2008
141. Servier sales (PLN m) and y-o-y change on the Polish pharmacy market, 2002-2008
142. Roche sales (PLN m) and y-o-y change on the Polish pharmacy market, 2002-2008
143. Roche Rx sales (PLN m) and y-o-y change on the Polish pharmacy market, 2002-2008
144. Krka sales (PLN m) and y-o-y change on the Polish pharmacy market, 2002-2008
145. Krka Rx sales (PLN m) and y-o-y change on the Polish pharmacy market, 2002-2008
146. Krka’s sales performance (€ m) and y-o-y change in Central Europe, Q1 2009
147. US Pharmacia sales (PLN m) and y-o-y change on the Polish pharmacy market, 2002-2008
148. Novo Nordisk sales (PLN m) and y-o-y change on the Polish pharmacy market, 2002-2008
149. Adamed sales (PLN m) and y-o-y change on the Polish pharmacy market, 2002-2008
150. Poland’s population (million), 2000-2035
151. Fertility rate in Poland and other select countries, 2008
152. Age structure of Polish population, 2000 and 2008
153. Population forecast for selected age groups in Poland (million), 2004-2035
154. Structure of health insurance spending in Poland, by age, in 2007, 2025 and 2050
155. Life expectancy at birth in Poland (years), 1990-2035
156. Expected lifespan at birth for men in Poland compared with select European countries, 1990 and 2006
157. Expected lifespan at birth for women in Poland compared with select European countries, 1990 and 2006
158. Polish population by gender, 2008
159. Polish population by place of residence, 2008
160. Did you suffer from the illness/ailment in the last year? Poland and EU average, 2008
161. Do you or someone in your household suffer from the mentioned illnesses/ailments? Poland, 2008
162. Deaths by main causes (% of total deaths) in Poland, 1990-2006
163. Surplus mortality in persons aged 25-64 in Poland relative to EU-27 average, by cause of death and gender, 1999 and 2006
164. Surplus mortality in persons aged 25-64 in Poland relative to EU-27 average, by disease and gender, 2006
165. Deaths caused by cardiovascular diseases, by type of disease, Poland, 2006
166. Number of cases of malignant tumours in men in Poland, by tumour localisation (‘000), 2006
167. Incidence of malignant tumours in men in Poland, by type of cancer, 1999, 2002 and 2006
168. Mortality rate among men caused by malignant tumorus, by type of cancer (‘000), 2006
169. Number of cases of malignant tumours in women in Poland, by tumour localisation (‘000), 2006
170. Incidence of malignant tumours in women in Poland, by type of cancer, 1999, 2002 and 2006
171. Mortality rate among women caused by malignant tumours, by type of cancer, Poland (‘000), 2006
172. Incidence of flu in Poland (million), 1970-2008
173. Morbidity rate (number of cases per 100,000 inhabitants) for hepatitis virus C in Poland, 1999-2007
174. Assessment of own health in Poland, 2008
175. Reasons for poor health in Poland in opinion of the respondents, 2008
176. What do Poles and Europeans do to stay healthy?, 2008
177. The 10 most frequently used sources on health information in Poland and their reliability, 2008
178. Doctors informing Polish patients about cheaper equivalents of expensive drugs, 2001, 2003, 2005 and 2007
179. Poles’ opinions on Polish equivalents of foreign drugs, 2005 and 2007
180. Respondents’ opinions about generic drugs in Poland and other European countries, 2008
181. Poles attitude towards innovative drugs and treatment, 2008
182. Factors influencing the purchase of OTC drugs in Poland and other European countries, 2008
183. The most prevalent opinions about OTC drugs in Poland and Europe, 2008
184. Most often purchased OTC drugs in Poland, April 2007-April 2008
185. Where do you purchase OTC drugs in Poland? 2007
186. Consumer confidence in online drug distribution channels in Poland, 2008
187. Most popular reasons not to purchase OTC drugs in e-pharmacies in Poland, 2008
188. Use of OTC and Rx drugs to treat illnesses/ailments in Poland, 2008
189. GDP growth in Poland (%), 2005-2011
190. Inflation rate in Poland (%), 2005-2011
191. Unemployment rate in Poland (%), 2005-2011
192. Gross average monthly wages in Poland (PLN), 2005-2008
193. End statistics for harmonisation of medicinal products in Poland, January 2009
194. Revenues and net profit of Cefarm Bialystok in Poland (PLN m), 2007-2008
195. Revenues and net profit of CF Cefarm in Poland (PLN m), 2007-2008
196. Pharmaceuticals distribution in Poland, 2007
197. Number of pharmaceutical warehouses owned by the largest wholesalers in Poland, 2008
198. Wholesaler count in Poland and select European countries, 2007
199. Market share of largest pharmaceutical wholesalers in Poland, 2008
200. PGF’s total revenues, net profits and y-o-y change (PLN m), 2007-2008
201. PGF’s total revenues, net profits and y-o-y change (PLN m), Q1 2009
202. PGF sales structure, 2008
203. Torfarm’s total revenues, net profits and y-o-y change in Poland (PLN m), 2007-2008
204. Torfarm’s total revenues, net profits and y-o-y change in Poland (PLN m), Q1 2009
205. Farmacol’s total revenues, net profits and y-o-y change in Poland (PLN m), 2007-2008
206. Farmacol’s total revenues, net profits and y-o-y change in Poland (PLN m), Q1 2009
207. Prosper’s total revenues, net profits and y-o-y change in Poland (PLN m), 2007-2008
208. Prosper’s total revenues, net profits and y-o-y change in Poland (PLN m), Q1 2009
209. OPG Groep’s sales and y-o-y change in Poland (€ m), 2007-2008
210. OPG Groep’s sales and y-o-y change in Poland (€ m), Q1 2009
211. Number of pharmacies and pharmacy outlets in Poland (thousands), 1990-2008
212. Average monthly pharmacy sales in Poland (PLN ‘000) and y-o-y change, January 2007-December 2008
213. Pharmacy chains in Poland (pharmacy count), January 2009
214. The largest independent pharmacy chains in Poland, April 2009
215. Online pharmacies’ sales of medicinal products and cosmetics (PLN m), 2007 and 2013
216. The biggest online pharmacies in Poland (number of unique users in thousand), August 2008
217. Total healthcare sector’s financing (PLN bn) in Poland, 2000-2007
218. Sources of financing in healthcare sector in Poland, 2007
219. Forecast for total financing and spending of public healthcare sector (PLN bn) in Poland, 2008-2050
220. Proceeds from health insurance premiums (PLN m) in Poland, 2000-2007
221. State budget expenditure on public health insurance premiums in Poland, by insured, 2007 and 2008
222. Healthcare system spending in Poland (PLN bn), 2004-2007
223. Healthcare spending in Poland, by function, 2006
224. Healthcare spending in Poland, by provider groups, 2006
225. State budget spending on health care (PLN m) in Poland, 1999-2007
226. Funds spent on health care by individual local government units in Poland, 2007
227. NFZ expenditure on reimbursement in Poland (PLN bn), 2001-2007
228. NFZ’s net financial result in Poland (PLN m), 2004-2007
229. Number of public and non-public hospitals in Poland, 2001-2007

List of tables

1. Value (PLN m) and y-o-y change of pharmaceutical sales on the pharmacy market in Poland, by ATC groups, 2002-2008
2. Value (PLN m) and y-o-y change of Rx pharmaceutical sales on the pharmacy market in Poland, by ATC groups, 2002-2008
3. Value (PLN bn) and y-o-y change of pharmaceutical market in Poland, pharmacy market, Rx market and reimbursed drugs, 2002-2008
4. Volume (million of packages) and y-o-y change of sales on the pharmaceutical market in Poland, pharmacy market, Rx market and reimbursed drugs, 2002-2008
5. Value (PLN bn) and y-o-y change of sales of domestic and foreign drugs in Poland, pharmacy market, Rx market, and reimbursed drugs, 2002-2008
6. Volume (million of packages) and y-o-y change of sales of domestic and foreign drugs in Poland, pharmacy market, Rx market, and reimbursed drugs, 2002-2008
7. Oncology drug therapy programmes in Poland, H1 2008
8. Hepatitis therapeutic programmes in Poland, 2008
9. Active substances which generated the highest reimbursement costs in Poland, 2006-H1 2008
10. Products generating highest drug reimbursement costs in Poland, 2006-2007
11. Products with the greatest quantity of reimbursed packages in Poland, 2006-2007
12. Manufacturers whose products generated the highest reimbursement value in Poland, 2007
13. Sales volume (million of packages) and y-o-y change of largest categories of drugs used in alimentary tract and metabolic diseases in Poland, pharmacy market and Rx market 2008
14. Top 10 drugs used in alimentary tract and metabolic diseases in Poland, by sales value, 2008
15. Value (PLN m) and y-o-y change of net profit and pre-tax profit of Polish pharmaceutical sector, 2002-2007
16. Percentage share of individual types of costs in total operating expenses of Polish pharmaceutical sector (%), 2002-2007
17. Employment in Polish pharmaceutical sector (staffing levels and y-o-y change), 2001-2007
18. Labour productivity in Polish pharmaceutical sector (PLN’000 per capita), 2001-2007
19. Major foreign investment projects in Polish pharmaceutical industry, 2007
20. Top 20 pharma concerns on the Polish pharmacy market, in terms of sales value and volume, 2008
21. Top 20 pharma manufacturers on the Polish pharmacy market, in terms of sales value and volume, 2008
22. Top 20 pharma concerns on the Polish Rx pharmacy market, in terms of sales value and volume, 2008
23. Top 20 pharma manufacturers on the Polish Rx pharmacy market, in terms of sales value and volume, 2008
24. Novartis’ products among best sellers of individual ATC categories in Poland, 2008
25. Sandoz products among best sellers of individual ATC categories in Poland, 2008
26. GSK products among best sellers of individual ATC categories in Poland, 2008
27. Polpharma products among best sellers of individual ATC categories in Poland, 2008
28. Sanofi-Aventis products among best sellers of individual ATC categories in Poland, 2008
29. Servier products among best sellers of individual ATC categories in Poland, 2008
30. Roche products among best sellers of individual ATC categories in Poland, 2008
31. Krka products among best sellers of individual ATC categories in Poland, 2008
32. US Pharmacia products among best sellers of individual ATC categories in Poland, 2008
33. Novo Nordisk products among best sellers of individual ATC categories in Poland, 2008
34. Adamed products among best sellers of individual ATC categories in Poland, 2008
35. Number of persons treated in psychiatric care out-patient clinics and all-day hospital wards in Poland, by select diagnosis, 2000-2006
36. Number of persons with diabetes in Poland and in other countries of Central and Eastern Europe (‘000), 1994-2010
37. Official retail margins for reimbursed drugs provided in the draft of the minor amendment to the Pharmaceutical Law in Poland, September 2008
38. Torfarm’s acquisition record, 2007-2009
39. Financing from healthcare premiums (PLN m) in Poland, by ZUS and KRUS inflows, 2000-2007
40. Costs of financial tasks from the state budget (PLN m) in Poland, 2004-2007
41. Structure of local government unit spending on health care (PLN m) in Poland, by healthcare division, 2007
42. Persons insured with the NFZ in Poland, 2004-2007
43. Registered medical personnel in Poland, 2001-2007
44. Medical personnel employed at healthcare facilities in Poland, 2001-2007
45. Specialists employed at healthcare facilities, 2006-2007
46. Average net monthly remuneration in independent public healthcare centres based on employment contracts in Poland, by select professional groups, June 2007
47. Number of healthcare centres (ZOZ) and outpatient assistance in Poland, 2000-February 2009
48. Primary healthcare facilities (POZ) in Poland, 2003-2007
49. Number of beds and hospitalised in general hospitals in Poland, 2005-2007
50. Poles' monthly healthcare spending (PLN per capita), 2007
51. Main reasons for hospitalisation in Poland, 2006